Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Serina Therapeutics (SER) Return on Sales (2018 - 2025)

Serina Therapeutics (SER) has disclosed Return on Sales for 8 consecutive years, with 186.42% as the latest value for Q4 2025.

  • Quarterly Return on Sales fell 58399.0% to 186.42% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 186.42% through Dec 2025, up 12740.0% year-over-year, with the annual reading at 147.81% for FY2025, 5232.0% up from the prior year.
  • Return on Sales hit 186.42% in Q4 2025 for Serina Therapeutics, up from 201.69% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 397.57% in Q4 2024 to a low of 541.4% in Q1 2022.
  • Historically, Return on Sales has averaged 151.3% across 5 years, with a median of 116.13% in 2023.
  • Biggest five-year swings in Return on Sales: skyrocketed 50647bps in 2023 and later crashed -58399bps in 2025.
  • Year by year, Return on Sales stood at 0.72% in 2021, then plummeted by -48133bps to 345.0% in 2022, then soared by 100bps to 0.02% in 2023, then surged by 1888058bps to 397.57% in 2024, then plummeted by -147bps to 186.42% in 2025.
  • Business Quant data shows Return on Sales for SER at 186.42% in Q4 2025, 201.69% in Q3 2025, and 42.88% in Q2 2025.